Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Future is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity

Author(s): Rami A. Al-Horani*, Kholoud F. Aliter and Hashem F. Aliter

Volume 20, Issue 8, 2024

Published on: 23 January, 2024

Article ID: e230124226019 Pages: 14

DOI: 10.2174/0115733998276832231124170324

Price: $65

conference banner
Abstract

Diabetes is a chronic illness that can become debilitating owing to its microvascular and macrovascular complications. Its prevalence is increasing and so is its cost. Diabetes, particularly type 2, appears to have a very close relationship with obesity. While lifestyle modifications, exercises, and current therapeutics have substantially improved clinical outcomes, the need for new therapeutics and regimens continue to exist. Several new medications and regimens for diabetes, obesity, and diabesity are showing promising results in advanced clinical trials. For type 1 diabetes mellitus (T1DM), they include teplizumab, ustekinumab, jakinibs, and cell therapies, whereas for type 2 diabetes mellitus (T2DM), they include once-weakly insulin, tirzepatide, high oral dose of semaglutide, orforglipron, retatrutide, CagriSema, and survodutide. Given their structural and mechanistic diversity as well as their substantial efficacy and safety profiles, these medications and regimens are paradigm shifting and promise a brighter future. They will likely enable better disease prevention and management. This review will provide details about each of the above strategies to keep the scientific community up to date about progress in the fields of diabetes and obesity.

Keywords: Diabetes, obesity, insulin, semaglutide, teplizumab, orforglipron, retatrutide, tirzepatide, survodutide, cagrisema, ustekinumab, jakinibs.

[1]
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018. Diabetes Care 2018; 41(S1): S13-27.
[http://dx.doi.org/10.2337/dc18-S002] [PMID: 29222373]
[2]
Merger SR, Leslie RD, Boehm BO. The broad clinical phenotype of Type 1 diabetes at presentation. Diabet Med 2013; 30(2): 170-8.
[http://dx.doi.org/10.1111/dme.12048] [PMID: 23075321]
[3]
Carson AP, Reynolds K, Fonseca VA, Muntner P. Comparison of A1C and fasting glucose criteria to diagnose diabetes among U.S. adults. Diabetes Care 2010; 33(1): 95-7.
[http://dx.doi.org/10.2337/dc09-1227] [PMID: 19808920]
[4]
Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006. Diabetes Care 2010; 33(3): 562-8.
[http://dx.doi.org/10.2337/dc09-1524] [PMID: 20067953]
[5]
Malkani S, Mordes JP. Implications of using hemoglobin A1C for diagnosing diabetes mellitus. Am J Med 2011; 124(5): 395-401.
[http://dx.doi.org/10.1016/j.amjmed.2010.11.025] [PMID: 21531226]
[6]
Meijnikman AS, De Block CEM, Dirinck E, et al. Not performing an OGTT results in significant underdiagnosis of (pre)diabetes in a high risk adult Caucasian population. Int J Obes 2017; 41(11): 1615-20.
[http://dx.doi.org/10.1038/ijo.2017.165] [PMID: 28720876]
[7]
Diabetes Statistics. Available from: https://www.niddk.nih.gov/health-information/health-statistics/diabetes-statistics (Accessed on: July 29, 2023).
[8]
American Diabetes Association. Available from: https://diabetes.org/about-us/statistics/cost-diabetes (Accessed on: July 29, 2023).
[9]
Menke A, Rust KF, Fradkin J, Cheng YJ, Cowie CC. Associations between trends in race/ethnicity, aging, and body mass index with diabetes prevalence in the United States: A series of cross-sectional studies. Ann Intern Med 2014; 161(5): 328-35.
[http://dx.doi.org/10.7326/M14-0286] [PMID: 25178569]
[10]
Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122(7): 481-6.
[http://dx.doi.org/10.7326/0003-4819-122-7-199504010-00001] [PMID: 7872581]
[11]
DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14(3): 173-94.
[http://dx.doi.org/10.2337/diacare.14.3.173] [PMID: 2044434]
[12]
Friedman JE, Dohm GL, Leggett-Frazier N, et al. Restoration of insulin responsiveness in skeletal muscle of morbidly obese patients after weight loss. Effect on muscle glucose transport and glucose transporter GLUT4. J Clin Invest 1992; 89(2): 701-5.
[http://dx.doi.org/10.1172/JCI115638] [PMID: 1737857]
[13]
Del Prato S, Bonadonna RC, Bonora E, et al. Characterization of cellular defects of insulin action in type 2 (non-insulin-dependent) diabetes mellitus. J Clin Invest 1993; 91(2): 484-94.
[http://dx.doi.org/10.1172/JCI116226] [PMID: 8432857]
[14]
Fryar CD, Carroll MD, Afful J. Prevalence of overweight, obesity, and severe obesity among adults aged 20 and over: United States, 1960–1962 through 2017–2018. 2020. Available from: www.cdc.gov/nchs/data/hestat/obesity-adult-17-18/obesity-adult.htm (Accessed on: July 29, 2023).
[15]
Fryar CD, Carroll MD, Afful J. Prevalence of overweight, obesity, and severe obesity among children and adolescents aged 2–19 years: United States, 1963–1965 through 2017–2018. 2021. Available from: www.cdc.gov/nchs/data/hestat/obesity-child-17-18/overweight-obesity-child-H.pdf (Accessed on: July 29, 2023).
[16]
Al-Horani RA, Chedid M. Tirzepatide: A new generation therapeutic for diabetes type 2. Endocr Metab Immune Disord Drug Targets 2023; 23(8): 1046-50.
[http://dx.doi.org/10.2174/1871530322666221004151212] [PMID: 36200219]
[17]
American Diabetes Association. Available from: https://professional.diabetes.org/scientific-sessions (Accessed on: July 18, 2023).
[18]
Gaglia J, Kissler S. Anti-CD3 antibody for the prevention of type 1 diabetes: A story of perseverance. Biochemistry 2019; 58(40): 4107-11.
[http://dx.doi.org/10.1021/acs.biochem.9b00707] [PMID: 31523950]
[19]
TZIELD™ (teplizumab-mzwv) injection, for intravenous use Initial U.S. Approval: 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761183s000lbl.pdf (Accessed on: July 19, 2023).
[20]
ElSayed NA, Aleppo G, Aroda VR. Classification and diagnosis of diabetes: Standards of care in diabetes-2023. Diabetes Care 2023; 46(S1): S19-40.
[21]
ElSayed NA, Aleppo G, Aroda VR. Addendum. 3. Prevention or delay of type 2 diabetes and associated comorbidities: Standards of care in diabetes-2023. Diabetes Care 2023; 46(S1): S41-8.
[22]
Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 2019; 381(7): 603-13.
[http://dx.doi.org/10.1056/NEJMoa1902226] [PMID: 31180194]
[23]
Marwaha AK, Chow S, Pesenacker AM. A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes. Immunother Adv 2021; 2(1): ltab022.
[24]
Gregory JW, Carter K, Cheung WY, et al. Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): Trial protocol. BMJ Open 2021; 11(10): e049595.
[http://dx.doi.org/10.1136/bmjopen-2021-049595] [PMID: 34663658]
[25]
Chaimowitz NS, Ebenezer SJ, Hanson IC, Anderson M, Forbes LR. STAT1 gain of function, type 1 diabetes, and reversal with JAK inhibition. N Engl J Med 2020; 383(15): 1494-6.
[http://dx.doi.org/10.1056/NEJMc2022226] [PMID: 33027576]
[26]
Zeng Q, Song J, Wang D, et al. Identification of sorafenib as a treatment for type 1 diabetes. Front Immunol 2022; 13: 740805.
[http://dx.doi.org/10.3389/fimmu.2022.740805] [PMID: 35242127]
[27]
Waibel M, Thomas HE, Wentworth JM, et al. Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)—study protocol for a phase 2, randomized, placebo controlled trial. Trials 2022; 23(1): 433.
[http://dx.doi.org/10.1186/s13063-022-06356-z] [PMID: 35606820]
[28]
Vertex announces FDA clearance of investigational new drug (IND) application for VX-880, a novel cell therapy for the treatment of type 1 diabetes (T1D). Available from: https://news.vrtx.com/news-releases/news-release-details/vertex-announces-fda-clearance-investigational-new-drug-ind (Accessed on: July 20, 2023).
[29]
A safety, tolerability and efficacy study of sernova's cell pouch™ for clinical islet transplantation. Patent NCT03513939, 2022.
[30]
Syed F, Ballew O, Lee CC, et al. 25-OR: ADA presidents’ select abstract: Preclinical evaluation of TYK2 inhibitors in type 1 diabetes. Diabetes 2023; 72(S1): 25-OR.
[http://dx.doi.org/10.2337/db23-25-OR]
[31]
Rosenstock J, Bain SC, Gowda A, et al. Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin. N Engl J Med 2023; 389(4): 297-308.
[http://dx.doi.org/10.1056/NEJMoa2303208] [PMID: 37356066]
[32]
Lingvay I, Asong M, Desouza C, et al. Once-weekly insulin icodec vs once-daily insulin degludec in adults with insulin-naive type 2 diabetes. JAMA 2023; 330(3): 228-37.
[http://dx.doi.org/10.1001/jama.2023.11313] [PMID: 37354562]
[33]
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022; 387(3): 205-16.
[http://dx.doi.org/10.1056/NEJMoa2206038] [PMID: 35658024]
[34]
Garvey WT, Frias JP, Jastreboff AM. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023; 402(10402): 613-26.
[35]
Hughes S, Neumiller JJ. Oral semaglutide. Clin Diabetes 2020; 38(1): 109-11.
[http://dx.doi.org/10.2337/cd19-0079] [PMID: 31975761]
[36]
Knop FK, Aroda VR, do Vale RD. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 402(10403): 705-19.
[37]
Aroda VR, Aberle J, Bardtrum L. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): A multicentre, randomised, phase 3b trial. Lancet 2023; 402(10403): 693-704.
[38]
Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med 2023; 389(10): 877-88.
[http://dx.doi.org/10.1056/NEJMoa2302392] [PMID: 37351564]
[39]
Frias JP, Hsia S, Eyde S. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: A multicentre, randomised, dose-response, phase 2 study. Lancet 2023; 402(10400): 472-83.
[http://dx.doi.org/10.1016/S0140-6736(23)01302-8]
[40]
Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab 2022; 34(9): 1234-1247.e9.
[http://dx.doi.org/10.1016/j.cmet.2022.07.013] [PMID: 35985340]
[41]
Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med 2023; 389(6): 514-26.
[http://dx.doi.org/10.1056/NEJMoa2301972] [PMID: 37366315]
[42]
Rosenstock J, Frias J, Jastreboff AM. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: A randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 2023; 402(10401): 529-44.
[43]
Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: Pharmacology, physiology, and clinical potential. Pharmacol Rev 2015; 67(3): 564-600.
[http://dx.doi.org/10.1124/pr.115.010629] [PMID: 26071095]
[44]
Kruse T, Hansen JL, Dahl K, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem 2021; 64(15): 11183-94.
[http://dx.doi.org/10.1021/acs.jmedchem.1c00565] [PMID: 34288673]
[45]
Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: A randomised, controlled, phase 1b trial. Lancet 2021; 397(10286): 1736-48.
[http://dx.doi.org/10.1016/S0140-6736(21)00845-X] [PMID: 33894838]
[46]
Frias JP, Deenadayalan S, Erichsen L. Efficacy and safety of co-administered once-weekly cagrilintide 2•4 mg with once-weekly semaglutide 2•4 mg in type 2 diabetes: A multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet 2023; 402(10403): 720-30.
[47]
Zimmermann T, Thomas L, Baader-Pagler T, et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab 2022; 66: 101633.
[http://dx.doi.org/10.1016/j.molmet.2022.101633] [PMID: 36356832]
[48]
Le Roux CW, Steen O, Lucas KJ. 51-OR: A phase 2, randomized, double-blind, placebo-controlled, dose-finding study of BI 456906 in people with overweight/obesity. Diabetes 2023; 72(S1): 51-OR.
[http://dx.doi.org/10.2337/db23-51-OR]
[49]
Pettus J, Boeder SC, Christiansen MP, et al. Glucagon receptor antagonist volagidemab in type 1 diabetes: A 12-week, randomized, double-blind, phase 2 trial. Nat Med 2022; 28(10): 2092-9.
[http://dx.doi.org/10.1038/s41591-022-02011-x] [PMID: 36192552]
[50]
Ji L, Gao L, Jiang H, et al. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine 2022; 54: 101691.
[http://dx.doi.org/10.1016/j.eclinm.2022.101691] [PMID: 36247927]

Rights & Permissions Print Cite
Article Metrics
56
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy